Cancer · 1970 · 30 citations · 26 references
MedicineOncologyPharmacologyCancer PharmacologyCarcinogenesisTumor PathologyMalignant NeoplasmsRodent OncologyCarcinogenic ResponseChemical Carcinogen ExposureCumulative Dose AssessmentCumulative Dose EvaluationDose-response Tumorigenicity TestingMechanisms Of CarcinogenicityRodent Tumor Models
4(5)-(3,3-dimethyl-l-triazeno)imidazole-5(4)-carboxamide (DICNSC 45388)and anticancer drug with activity against rodent and human tumorswas tested for carcinogenic activity by feeding a mean cumulative dose of 740 mg/rat/14 weeks to 24 female Sprague-Dawley weanling rats. The first mammary tumor was palpated 10 weeks after the start of feeding DICand by 18 weekswhen the experiment was terminatedall 24 rats had developed an average of 5 mammary adenocarcinomas. Lymphosarcoma was present in the thymus of all rats and in the spleen (20/24)lymph nodes (18/24)and bone marrow (12/24). Ependymomas of the brain were present in 9 rats and pulmonary alveolar carcinomas in 4 rats. No tumors were found in the negative control group of 24 rats. DIC appears to be a potent chemical carcinogen that may exert its carcinogenic activity by the alkylation of biopolymers.
26
Emil J. Freireich, E. A. Gehan, David P. Rall et al. · PubMed · 1966 · 1.4K citations
Pharmacy, Oncology, Toxicology +14